Trial Profile
A Phase 1, Open-Label, Parallel Group Trial to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single Intravenous Dose of TAK-954
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Apr 2021
Price :
$35
*
At a glance
- Drugs Felcisetrag (Primary)
- Indications Diabetic gastroparesis; Gastrointestinal motility disorders
- Focus Pharmacokinetics
- Sponsors Takeda
- 21 Aug 2019 Status changed from recruiting to completed.
- 24 Jul 2019 Planned End Date changed from 30 Aug 2019 to 10 Aug 2019.
- 24 Jul 2019 Planned primary completion date changed from 15 Jul 2019 to 10 Aug 2019.